Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
drug treatment · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| drug treatment | DRUG | - |
Inclusion criteria: •Male or non-pregnant women (only women who are post menopausal, surgically sterile or practicing a reliable method of contraception may be included) aged 20 years or more * Meeting the Modified New York diagnostic criteria for AS (Van der Linden S et al., 1984) * Symptoms of ac...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY002-072 |
| XBiotech, Inc. | XBIT | 1 | PHASE2 | vilamakitug |
| Sunshine Biopharma Incorporated | SBFM | 2 | PHASE3 | Undisclosed |
| AbbVie, Inc. | ABBV | 1 | - | Upadacitinib |
| Novartis AG Sponsored ADR | NVS | 1 | - | Secukinumab |
| Pfizer Inc. | PFE | 1 | - | Tofacitinib |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
Drug treatment is an investigational small molecule being studied for ankylosing spondylitis, a type of inflammatory arthritis affecting the spine. It is currently in Phase 2 clinical development. The drug has not been approved by the FDA and remains under investigation for this condition.
Sanofi (ticker: SNY) is developing drug treatment. The company is conducting clinical research on this investigational small molecule for ankylosing spondylitis. Sanofi is responsible for the ongoing development and potential commercialization of the drug.
Drug treatment is in Phase 2 clinical development for ankylosing spondylitis. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. The Phase 2 trial has been completed, and the drug is still being evaluated for safety and efficacy.
Drug treatment has one completed Phase 2 clinical trial registered as NCT01038011, titled 'Efficacy and Safety of Risedronate (Actonel), a Third Generation Bisphosphonate in Patients With Ankylosing Spondylitis: a Phase 2 Pilot Study.' The trial was conducted in Switzerland and enrolled adults aged 18 years and older.
Drug treatment is also known as risedronate, marketed under the brand name Actonel. It is a third-generation bisphosphonate being investigated for ankylosing spondylitis. The Phase 2 trial NCT01038011 specifically evaluated risedronate in patients with this condition.